Company Overview of Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company that focuses on the discovery of molecules and therapies to help improve the lives of people who suffer from rare diseases in Canada. The company develops prescription pharmaceuticals, including Cystaran, a cysteamine ophthalmic solution; Carnitor levocarnitine tablets, oral solution, sugar-free oral solution, and injection; Carnitor, a levocarnitine injection; Matulane procarbazine hydrochloride capsules; Adagen, a pegademase bovine; Abelcet, an amphotericin B lipid complex injection; and DepoCyt, a cytarabine liposome injection. It also develops nonprescription medicines and dietary supplements. The company was foun...
9841 Washingtonian Boulevard
Gaithersburg, MD 20878
Founded in 1980
Key Executives for Sigma-Tau Pharmaceuticals, Inc.
Vice President of Finance
Chief Executive Officer of Sigma-Tau Group
Senior Director of Legal Affairs & Compliance
Vice President of Medical Affairs
Compensation as of Fiscal Year 2016.
Sigma-Tau Pharmaceuticals, Inc. Key Developments
Sigma-Tau Pharmaceuticals, Inc. Appoints Michael Minarich as Chief Executive Officer
Aug 4 16
Sigma-Tau Pharmaceuticals, Inc. announced that its Board of Directors has appointed Michael Minarich as the company’s Chief Executive Officer (CEO), effective July 13, 2016. Mr. Minarich has served as interim Chief Executive Officer of the company since July 2015. He spent the previous 20 years as an expatriate in Asia (Seoul), Canada (Montreal) and Europe (Brussels & Prague) as the Market Company President, Czech Republic for Pharmacia Corporation and at legacy company, G.D. Searle /Monsanto, with increasing responsibilities in international General Management, Marketing and Business Development.
Sigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis
Apr 1 15
Sigma-Tau Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for the company's investigational compound, STP-206 (lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis), a live biotherapeutic being developed for the prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1,500 grams. The company is currently conducting a multi-center, double-blind, randomized, placebo-controlled Phase 1b/2a clinical trial for STP-206 at a number of different sites in the United States. An Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the beneficiary company with a seven-year period of U.S. marketing exclusivity if it is the first product to reach marketing approval, as well as potential tax credits for clinical research costs, federal grants, and a waiver of Prescription Drug User Fee Act (PDUFA) filing fees.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|